These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 18326358)

  • 61. Newer progestogens.
    Rowlands S
    J Fam Plann Reprod Health Care; 2003 Jan; 29(1):13-6. PubMed ID: 12626173
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Angioedema and estrogen-dependent angioedema with activation of the contact system.
    Hentges F; Hilger C; Kohnen M; Gilson G
    J Allergy Clin Immunol; 2009 Jan; 123(1):262-4. PubMed ID: 19130939
    [No Abstract]   [Full Text] [Related]  

  • 63. Medical eligibility criteria for new contraceptive methods: combined hormonal patch, combined hormonal vaginal ring and the etonogestrel implant.
    Gaffield ME; Curtis KM; Mohllajee AP; Peterson HB
    Contraception; 2006 Feb; 73(2):134-44. PubMed ID: 16413844
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Low-dose progestogen contraception and the nursing mother.
    Toddywalla VS; Patel SB; Betrabet SS; Saxena BN
    Adv Contracept; 1995 Dec; 11(4):285-94. PubMed ID: 8659313
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Hormonal contraception].
    Imparato E
    Rass Int Clin Ter; 1970 Jan; 50(2):86-96. PubMed ID: 5436775
    [No Abstract]   [Full Text] [Related]  

  • 66. [Complications of hormonal contraception with estrogen and gestagens in the climacteric and in the postmenopausal period. 39th Congress of the "Zurich Discussion Group", October 2007].
    Birkhäuser M; Braendle W; Kuhl H; Neulen J; Thaler CJ
    Gynakol Geburtshilfliche Rundsch; 2009; 49(1):45-51. PubMed ID: 19204402
    [No Abstract]   [Full Text] [Related]  

  • 67. Safety of oral contraceptives related to steroid content: a critical review.
    Sturtevant FM
    Int J Fertil; 1989; 34(5):323-32. PubMed ID: 2571592
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Options of hormonal contraceptives and substitution in female diabetic patients].
    Sadlonová J
    Vnitr Lek; 2009 Apr; 55(4):375-83. PubMed ID: 19449754
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Red cell deformability in oral contraceptive pill users with sickle cell anaemia.
    Yoong WC; Tuck SM; Yardumian A
    Br J Haematol; 1999 Mar; 104(4):868-70. PubMed ID: 10192452
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Female hormones and oral health].
    Meijer van Putten JB
    Ned Tijdschr Tandheelkd; 1998 Nov; 105(11):416-8. PubMed ID: 11928463
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The transdermal patch and the vaginal ring: two novel methods of combined hormonal contraception.
    Swica Y
    Obstet Gynecol Clin North Am; 2007 Mar; 34(1):31-42, viii. PubMed ID: 17472863
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Veno-lymphatic insufficiency. 4,729 patients undergoing hormonal and procyanidol oligomer therapy].
    Henriet JP
    Phlebologie; 1993; 46(2):313-25. PubMed ID: 8362014
    [No Abstract]   [Full Text] [Related]  

  • 73. Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa).
    Shapiro S; Rosenberg L; Hoffman M; Kelly JP; Cooper DD; Carrara H; Denny LE; du Toit G; Allan BR; Stander IA; Williamson AL
    Cancer Causes Control; 2003 Jun; 14(5):485-95. PubMed ID: 12946044
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Contraceptives' role in HIV transmission is examined.
    AIDS Alert; 1996 Mar; 11(3):30-1. PubMed ID: 11363241
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [The risk-benefit balance of estrogen-progestogen hormonal contraception].
    Plu-Bureau G; Raccah-Tebeka B
    Med Sci (Paris); 2022 Jan; 38(1):59-69. PubMed ID: 35060888
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Calculation of estrogenic and gestagenic activity of oral hormonal contraceptive agents including a tabular review].
    Kless-Och M
    Schweiz Rundsch Med Prax; 1972 Nov; 61(46):1418-24. PubMed ID: 5084999
    [No Abstract]   [Full Text] [Related]  

  • 78. [Benefits and risk of the modern combined hormonal contraception].
    Fait T; Nouzová K; Sýkorová P; Fanta M; Vrablík M; Skrenková J
    Cas Lek Cesk; 2005; 144(4):238-44. PubMed ID: 15945482
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Helping women choose appropriate hormonal contraception: update on risks, benefits, and indications.
    Spencer AL; Bonnema R; McNamara MC
    Am J Med; 2009 Jun; 122(6):497-506. PubMed ID: 19486709
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Oestroprogestagens and severe acute pyelonephritis: a casual or causal association?
    Piccoli GB; Colla L; Mezza E; Burdese M; Cammarota T; Piccoli G
    Nephrol Dial Transplant; 2006 Aug; 21(8):2337. PubMed ID: 16868038
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.